All Stories

  1. Prognostic nutritional index as an early predictor of mortality in patients with severe fever with thrombocytopenia syndrome: multicenter retrospective study in South Korea

    Article • BMC Infectious Diseases, February 2025, Springer Science + Business Media

    Jaeseong Oh

  2. Population pharmacokinetic and pharmacodynamic model of evogliptin: Severe uremia increases the bioavailability of evogliptin

    Article • CPT Pharmacometrics & Systems Pharmacology, October 2024, Wiley

    Jaeseong Oh

  3. Coadministration of Voriconazole and Rifabutin Can Increase the Risk of Adverse Drug Reactions in Patients with Multiple Infections

    Article • Therapeutic Drug Monitoring, July 2024, Wolters Kluwer Health

    Jaeseong Oh

  4. Pharmacokinetic Interactions Between the Fixed-Dose Combination of Ezetimibe/Rosuvastatin 10/20 Mg and the Fixed-Dose Combination of Telmisartan/Amlodipine 80/5 Mg in Healthy Subjects

    Article • Drug Design Development and Therapy, July 2024, Taylor & Francis

    Jaeseong Oh

  5. A Population Pharmacokinetic Study to Compare a Novel Empagliflozin L-Proline Formulation with Its Conventional Formulation in Healthy Subjects

    Article • Pharmaceuticals, April 2024, MDPI AG

    Jaeseong Oh

  6. Effects of meal type on the bioavailability of vutiglabridin, a novel anti‐obesity agent, in healthy subjects

    Article • Clinical and Translational Science, March 2024, Wiley

    Jaeseong Oh

  7. Establishment of Advanced Regulatory Innovation for Clinical Trials Transformation (ARICTT): a multi-stakeholder public-private partnership-based organization to accelerate the transformation of clinical trials

    Article • Translational and Clinical Pharmacology, January 2024, XMLink

    Jaeseong Oh

  8. Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects

    Article • Investigational New Drugs, December 2023, Springer Science + Business Media

    Jaeseong Oh

  9. Topiramate dosage optimization for effective antiseizure management via population pharmacokinetic modeling

    Article • Annals of Clinical and Translational Neurology, December 2023, Wiley

    Jaeseong Oh

  10. Feasibility study for a fully decentralized clinical trial in participants with functional constipation symptoms

    Article • Clinical and Translational Science, August 2023, Wiley

    Jaeseong Oh

  11. Semimechanistic pharmacokinetic–pharmacodynamic model of tripegfilgrastim for pediatric patients after chemotherapy

    Article • CPT Pharmacometrics & Systems Pharmacology, August 2023, Wiley

    Jaeseong Oh

  12. Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects

    Article • Drug Design Development and Therapy, July 2023, Taylor & Francis

    Jaeseong Oh

  13. Continuous versus intermittent infusion of human antithrombin III concentrate in the immediate postoperative period after liver transplantation

    Article • Clinical and Translational Science, April 2023, Wiley

    Jaeseong Oh

  14. Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl‐tRNA synthetase inhibitor, in healthy subjects

    Article • Clinical and Translational Science, April 2023, Wiley

    Jaeseong Oh

  15. Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects

    Article • Pharmaceutics, February 2023, MDPI AG

    Jaeseong Oh

  16. Evaluation of Safety, Tolerability and Pharmacokinetic Characteristics of SA001 and Its Active Metabolite Rebamipide after Single and Multiple Oral Administration

    Article • Pharmaceuticals, January 2023, MDPI AG

    Jaeseong Oh

  17. Adaptive design clinical trials: current status by disease and trial phase in various perspectives

    Article • Translational and Clinical Pharmacology, January 2023, XMLink

    Jaeseong Oh

  18. pharmacokinetics, safety and tolerability of valbenazine in Korean CYP2D6 normal and intermediate metabolizers

    Article • Clinical and Translational Science, December 2022, Wiley

    Jaeseong Oh

  19. Reversal of rocuronium‐induced intense neuromuscular blockade by sugammadex in Korean children: A pharmacokinetic and pharmacodynamic analysis

    Article • Clinical and Translational Science, October 2022, Wiley

    Jaeseong Oh

  20. Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first‐in‐class, first‐in‐human study

    Article • Clinical and Translational Science, October 2022, Wiley

    Jaeseong Oh

  21. Pharmacokinetic evaluation of radiolabeled intraocular anti‐CLEC14a antibody in preclinical animal species and application in humans

    Article • Clinical and Translational Science, September 2022, Wiley

    Jaeseong Oh

  22. Clinical Evaluation of Digital Therapeutics: Present and Future

    Article • Healthcare Informatics Research, July 2022, The Korean Society of Medical Informatics (KAMJE)

    Jaeseong Oh

  23. The pharmacokinetic, safety, and tolerability profiles of eslicarbazepine acetate are comparable between Korean and White subjects

    Article • Clinical and Translational Science, June 2022, Wiley

    Jaeseong Oh

  24. Dose‐dependent glucosuria of DWP16001, a novel selective sodium–glucose cotransporter‐2 inhibitor, in healthy subjects

    Article • British Journal of Clinical Pharmacology, April 2022, Wiley

    Jaeseong Oh

  25. Therapeutic drug monitoring on the use of transplacental digoxin in fetal tachyarrhythmia: a case report

    Article • Translational and Clinical Pharmacology, January 2022, Korean Society for Clinical Pharmacology and Therapeutics (KAMJE)

    Jaeseong Oh

  26. Endogenous metabolic markers for predicting the activity of dihydropyrimidine dehydrogenase

    Article • Clinical and Translational Science, December 2021, Wiley

    Jaeseong Oh

  27. Population Pharmacokinetic Modelling and Simulation to Determine the Optimal Dose of Nanoparticulated Sorafenib to the Reference Sorafenib

    Article • Pharmaceutics, April 2021, MDPI AG

    Jaeseong Oh

  28. A meta-analysis: efficacy and safety of anti-epileptic drugs prescribed in Korea as monotherapy and adjunctive treatment for patients with focal epilepsy

    Article • Translational and Clinical Pharmacology, January 2021, Korean Society for Clinical Pharmacology and Therapeutics (KAMJE)

    Jaeseong Oh

  29. Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform

    Article • Translational and Clinical Pharmacology, January 2021, Korean Society for Clinical Pharmacology and Therapeutics (KAMJE)

    Jaeseong Oh

  30. Pharmacokinetic comparison between a fixed-dose combination of fimasartan/amlodipine/hydrochlorothiazide 60/10/25 mg and a corresponding loose combination of fimasartan/amlodipine 60/25 mg and hydrochlorothiazide 25 mg in healthy subjects

    Article • Translational and Clinical Pharmacology, January 2021, Korean Society for Clinical Pharmacology and Therapeutics (KAMJE)

    Jaeseong Oh

  31. Population Pharmacokinetic Analysis of Amikacin for Optimal Pharmacotherapy in Korean Patients with Nontuberculous Mycobacterial Pulmonary Disease

    Article • Antibiotics, November 2020, MDPI AG

    Jaeseong Oh

  32. Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects

    Article • Alimentary Pharmacology & Therapeutics, November 2020, Wiley

    Jaeseong Oh

  33. Pharmacokinetics and Tolerability of LC28-0126, a Novel Necrosis Inhibitor, After Multiple Ascending Doses: A Phase I Randomized, Double-blind, Placebo-controlled Study in Healthy Male Subjects

    Article • Clinical Therapeutics, October 2020, Elsevier

    Jaeseong Oh

  34. Pharmacokinetics of human antithrombin III concentrate in the immediate postoperative period after liver transplantation

    Article • British Journal of Clinical Pharmacology, February 2020, Wiley

    Jaeseong Oh

  35. Safety, tolerability and pharmacokinetics and pharmacodynamics of HL2351, a novel hybrid fc‐fused interleukin‐1 receptor antagonist, in healthy subjects: A first‐in‐human study

    Article • British Journal of Clinical Pharmacology, January 2020, Wiley

    Jaeseong Oh

  36. Evaluation of the pharmacokinetics and food effects of a novel formulation tamsulosin 0.4 mg capsule compared with a 0.2 mg capsule in healthy male volunteers

    Article • Translational and Clinical Pharmacology, January 2020, Korean Society for Clinical Pharmacology and Therapeutics (KAMJE)

    Jaeseong Oh

  37. Utility of Integrated Analysis of Pharmacogenomics and Pharmacometabolomics in Early Phase Clinical Trial: A Case Study of a New Molecular Entity

    Article • Genomics & Informatics, September 2018, Korea Genome Organization (KAMJE)

    Jaeseong Oh

  38. Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects

    Article • Alimentary Pharmacology & Therapeutics, June 2018, Wiley

    Jung Sunwoo, Jaeseong Oh

  39. Evaluation of the effects of food on levodropropizine controlled-release tablet and its pharmacokinetic profile in comparison to that of immediate-release tablet

    Article • Drug Design Development and Therapy, May 2018, Dove Medical Press

    Jaeseong Oh, Professor Beom-Jin Lee

  40. Performance of the Minto model for the target-controlled infusion of remifentanil during cardiopulmonary bypass

    Article • Anaesthesia, September 2017, Wiley

    Jaeseong Oh

  41. Safety, Tolerability, and Pharmacokinetic Characteristics of a Novel Nonopioid Analgesic, VVZ-149 Injections in Healthy Volunteers: A First-in-Class, First-in-Human Study

    Article • The Journal of Clinical Pharmacology, August 2017, Wiley

    Jaeseong Oh

  42. The novel carboxylesterase 1 variant c.662A>G may decrease the bioactivation of oseltamivir in humans

    Article • PLOS One, April 2017, PLOS

    Jaeseong Oh

  43. Pharmacokinetics, Pharmacodynamics and Tolerability of DWP14012, A Novel Acid Pump Antagonist, in Healthy Subjects

    Article • Gastroenterology, April 2017, Elsevier

    Jaeseong Oh

  44. Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers

    Article • Drug Design Development and Therapy, March 2017, Dove Medical Press

    Jaeseong Oh

  45. Prediction of serum theophylline concentrations and cytochrome P450 1A2 activity by analyzing urinary metabolites in preterm infants

    Article • British Journal of Clinical Pharmacology, January 2017, Wiley

    Jaeseong Oh

  46. Population pharmacokinetic analysis of cefdinir in healthy adults

    Article • Drug Metabolism and Pharmacokinetics, January 2017, Elsevier

    Kyoung Ryun Park, Jaeseong Oh

  47. Effects ofCYP2C19Genetic Polymorphisms on PK/PD Responses of Omeprazole in Korean Healthy Volunteers

    Article • Journal of Korean Medical Science, January 2017, Korean Academy of Medical Sciences (KAMJE)

    Jaeseong Oh

  48. Effects of renal impairment on the pharmacokinetics and pharmacodynamics of a novel dipeptidyl peptidase-4 inhibitor, evogliptin (DA-1229)

    Article • Diabetes Obesity and Metabolism, November 2016, Wiley

    Jaeseong Oh

  49. Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects

    Article • Drug Design Development and Therapy, August 2016, Dove Medical Press

    Jaeseong Oh

  50. Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

    Article • Journal of Visualized Experiments, July 2016, MyJove Corporation

    Jaeseong Oh

  51. Evaluation of factors associated with drug-induced liver injury using electronic medical records

    Article • Translational and Clinical Pharmacology, January 2016, Korean Society for Clinical Pharmacology and Therapeutics (KAMJE)

    Jaeseong Oh

  52. Inhibition of the multidrug and toxin extrusion (MATE) transporter by pyrimethamine increases the plasma concentration of metformin but does not increase antihyperglycaemic activity in humans

    Article • Diabetes Obesity and Metabolism, October 2015, Wiley

    Jaeseong Oh

  53. Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers

    Article • Antimicrobial Agents and Chemotherapy, May 2015, ASM Journals

    Jaeseong Oh

  54. Response to “Induction of both P-glycoprotein and specific cytochrome P450 by Aspirin eventually does not alter the antithrombotic effect of clopidogrel”

    Article • Clinical Pharmacology & Therapeutics, February 2015, Wiley

    Jaeseong Oh

  55. A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects

    Article • Drug Design Development and Therapy, February 2015, Taylor & Francis

    Professor Howard Lee, Jeong-Ae Kim, Jaeseong Oh

  56. Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-Trap in a rabbit model

    Article • Eye, January 2015, Springer Science + Business Media

    Jaeseong Oh

  57. Aspirin Decreases Systemic Exposure to Clopidogrel Through Modulation of P-Glycoprotein But Does Not Alter Its Antithrombotic Activity

    Article • Clinical Pharmacology & Therapeutics, February 2014, Springer Science + Business Media

    Jaeseong Oh

  58. A Randomized, Placebo Controlled, Double Blind, Parallel Group, Multiple Dosing, Dose Escalation Clinical Study to Evaluate Pharmacokinetics/Pharmacodynamics and Tolerability of Zofenopril in Healthy Korean Subjects

    Article • Journal of Korean Society for Clinical Pharmacology and Therapeutics, January 2013, Korean Society for Clinical Pharmacology and Therapeutics (KAMJE)

    Jaeseong Oh